Thymosin Alpha-1 vs SHLP2
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Thymosin Alpha-1
Thymosin Alpha-1 is a peptide naturally produced by the thymus gland that plays a crucial role in immune system modulation. It is approved in over 35 countries for various conditions including hepatitis B and C.
Full details →SHLP2
SHLP2 (Small Humanin-Like Peptide 2) is a mitochondrial-derived peptide similar to humanin. It has shown insulin-sensitizing and cytoprotective effects in research, with potential metabolic benefits.
Full details →Side-by-Side Comparison
| Aspect | Thymosin Alpha-1 | SHLP2 |
|---|---|---|
| Mechanism | Enhances T-cell function and maturation, stimulates dendritic cell activity, and modulates cytokine production. Promotes the differentiation of stem cells into mature T lymphocytes. | Enhances insulin sensitivity and glucose uptake. Provides cytoprotective effects similar to humanin. May act through similar but distinct receptor pathways. |
| Typical Dosage | Clinical dosing typically ranges from 1.6mg to 6.4mg administered subcutaneously 2-3 times weekly. Research protocols may vary. | Research compound with doses in the microgram to low milligram range studied in animal models. Human dosing not established. |
| Administration | Subcutaneous injection. Often used in cycles or as part of comprehensive immune support protocols. | Subcutaneous or intraperitoneal injection in research settings. Various SHLP analogs (1-6) have different properties. |
| Side Effects | Generally well-tolerated. Rare side effects include injection site reactions, mild flu-like symptoms, and temporary fatigue. | Limited data. Animal studies suggest good tolerability. May affect glucose metabolism. |
| Best For |